COTI (collar therapy indicator) has been recently introduced for the detection of gamma rays with emphasis on thyroid investigations. The aim of this study was to test the feasibility of a prototype version of COTI including activity detectors with low sensitivity in performing thyroid uptake measurements for a large group of patients. Consequently, thyroid uptake tests were carried out for a total of 89 patients (22 males and 67 females; age: 44 ± 13 years) with thyroid cancer (n = 74), hyperthyroidism (n = 16) at 2 and 24 h after administration of 0.44-2 MBq of 131I. Eight individuals among the thyroid cancer patients were monitored up to 96 h after administration. The COTI device was equipped with two CsI (Tl) detectors, known as LoHi type, sensitive to activity ranges from 0.02 to 30 MBq of 131I. The uptake values from COTI were compared with those measured with a standard probe. It was found that the mean uptake of thyroid activity in thyroid cancer patients was 2.1 ± 1.3% at 2 h when measured with the standard probe, while it was 2.2 ± 1.2% when measured with COTI. In addition, the average uptake at 24 h after administration was 2.5 ± 3.2% and 3.2 ± 3.8% measured with COTI and the standard probe, respectively. A strong correlation was found at 24 h between the results obtained with COTI and the standard probe, while a weaker correlation was seen at 2 h. Overall, there was no significant difference between the results obtained with the standard probe and those obtained with COTI at both 2 and 24 h (Pvalue ≥ 0.05). Besides, 85% of the uptake values measured with COTI were less than those measured with the standard probe at the 24 h after administration. The average uptake value was 0.9 ± 0.8% after 96 h by COTI, and 1.4 ± 1.3% by the standard probe. Pertaining to the hyperthyroidism patients, COTI showed mean uptake values of 20 ± 16% and 23 ± 18% at 2 and 24 h, respectively. In contrast, the standard probe suggested higher mean uptake values of 26 ± 18% and 30 ± 22%, respectively. It is concluded that the prototype of COTI used in the present study has been proved to be a feasible and promising tool in thyroid investigations. It is noted, however, that the next COTI generation should include detectors equipped with collimator and energy discrimination.

中文翻译：

---

131I示踪剂给药后使用便携式设备（COTI）进行的甲状腺摄取测试：概念验证。

最近已引入COTI（项圈治疗指标）来检测伽玛射线，重点是甲状腺检查。这项研究的目的是测试COTI原型版本的可行性，该原型版本的活动检测器在对大量患者进行甲状腺摄取测量时灵敏度较低。因此，在给药后2小时和24小时对总共89例患有甲状腺癌（n = 74），甲状腺功能亢进（n = 16）的甲状腺癌（n = 74），甲状腺功能亢进（n = 16）的患者进行了甲状腺摄取测试。 131I的0.44-2 MBq 甲状腺癌患者中的八个人在给药后长达96小时被监测。COTI设备配备了两个CsI（Tl）检测器，称为LoHi型，对131I的活动范围从0.02到30 MBq敏感。将COTI的吸收值与标准探针测得的值进行比较。发现使用标准探针测量时，甲状腺癌患者在2 h时平均摄取的甲状腺活性为2.1±1.3％，而当使用COTI测量时，其平均摄取为2.2±1.2％。另外，用COTI和标准探针测得，给药后24小时的平均摄取分别为2.5±3.2％和3.2±3.8％。用COTI和标准探针获得的结果在24 h时发现强相关，而在2 h时发现较弱的相关。总体而言，在2小时和24小时时，使用标准探针获得的结果与使用COTI获得的结果之间没有显着差异（Pvalue≥0.05）。除了，给药后24小时，使用COTI测量的摄取值的85％低于使用标准探针测量的摄取值。96小时后，COTI的平均摄取值为0.9±0.8％，而标准探针的平均摄取值为1.4±1.3％。与甲状腺功能亢进症患者有关，COTI在2小时和24小时的平均摄取值分别为20±16％和23±18％。相比之下，标准探针建议的平均摄取值分别更高，分别为26±18％和30±22％。结论是，本研究中使用的COTI原型已被证明是甲状腺研究中可行且有希望的工具。但是，应注意，下一代COTI应包括配备准直仪和能量识别器的探测器。与甲状腺功能亢进症患者有关，COTI在2小时和24小时的平均摄取值分别为20±16％和23±18％。相比之下，标准探针建议的平均摄取值分别更高，分别为26±18％和30±22％。结论是，本研究中使用的COTI原型已被证明是甲状腺研究中可行且有希望的工具。但是，应注意，下一代COTI应包括配备准直仪和能量识别器的探测器。与甲状腺功能亢进症患者有关，COTI在2小时和24小时的平均摄取值分别为20±16％和23±18％。相比之下，标准探针建议的平均摄取值分别更高，分别为26±18％和30±22％。结论是，本研究中使用的COTI原型已被证明是甲状腺研究中可行且有希望的工具。但是，应注意，下一代COTI应包括配备准直仪和能量识别器的探测器。结论是，本研究中使用的COTI原型已被证明是甲状腺研究中可行且有希望的工具。但是，应注意，下一代COTI应包括配备准直仪和能量识别器的探测器。结论是，本研究中使用的COTI原型已被证明是甲状腺研究中可行且有希望的工具。但是，应注意，下一代COTI应包括配备准直仪和能量识别器的探测器。